The role of pramipexole in a severe Parkinson s disease model in mice
|
|
- Valentine Stanley
- 6 years ago
- Views:
Transcription
1 Therapeutic Advances in Neurological Disorders Original Research The role of pramipexole in a severe Parkinson s disease model in mice Seham Gad ElHak, Abdel Aziz Ghanem, Hasan Abdelghaffar, Sahar ElDakroury, Dina ElTantawy, Sara ElDosouky and Mohamed Salama Ther Adv Neurol Disord (2010) 3(6) DOI: / ! The Author(s), Reprints and permissions: journalspermissions.nav Abstract: Background: Pramipexole is one of a new generation of dopamine agonists. Recently there have been questions regarding its neuroprotective effects. These effects have been tested against various insults, which have yielded conflicting results. Methods: In this study, we introduced a combination of 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP)/paraquat to induce a severe Parkinson s disease model. The mice, after receiving the combination of toxins, were evaluated using mortality rates and immunohistochemistry for degenerating tyrosine hydroxylase-positive neurons. Results and conclusions: Pramipexole was tested for its capacity to offer protection against neurotoxic the effects of MPTP/paraquat in this model; however, the results showed no improvement with pramipexole therapy. Keywords: MPTP, paraquat, neuroprotection, Parkinson s disease, pramipexole, mouse Introduction Parkinson s disease (PD) is the second most prevalent neurodegenerative disorder. Despite the long history of research regarding this disease, no satisfactory treatment has been found [Spencer et al. 2005]. One of the most valuable methods of studying PD is through animal models. Many neurotoxic models have been designed to study Parkinsonism in animals [Emborg, 2004]. These models, however, have failed to recapitulate all of the pathological findings in PD [Lane and Dunnett, 2008]. To improve accuracy, fusion of models has been suggested. This combinatorial method seems more relevant to the real pathogenesis of the disease, which makes it more capable of simulating the true pathological findings of PD [Dawson et al. 2002]. One popular toxin combination is the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)/ paraquat regimen. MPTP is a well-known neurotoxin and one of the classical chemicals used in PD modeling. Paraquat, on the other hand, is a pesticide that is used as a PD-inducing toxin in animals [Shepherd et al. 2006]. Combining these two drugs increases the severity of neuronal degeneration in a fashion similar to that induced by local 6-OH dopamine injection. This makes the MPTP/paraquat combination a reasonable substitute that can resolve many of the problems of 6-OH dopamine regarding mode of administration, unilateral lesions and lack of the progressive course of the model [Richter et al. 2008]. Pramipexole is a second-generation dopamine agonist with a better profile than the older generations [Hedlund and Perlmann, 2009]. New research suggests its capacity for neuroprotective effects [Winner et al. 2009]. Many pathways have been suggested for pramipexole neuroprotection, e.g. stimulation of dopaminergic neuron regeneration [Riaz and Bradford, 2005], antioxidant effects, inhibition of oligomerization of human a-synuclein and increased Bcl-2 immunoreactivity in dopaminergic neurons [Inden et al. 2009]. Since there is no perfect PD model, a neuroprotectant should be tested using multiple models [Anderson et al. 2006]. We think that evaluation Correspondence to: Mohamed Salama, MD Toxicology Department and Medical Experimental Research Center (MERC), ElGomhourya Street, toxicsalama@hotmail.com Seham Gad ElHak, MD Abdel Aziz Ghanem, MD Toxicology Department, Hasan Abdelghaffar, MD Medical Experimental Research Center (MERC) and Clinical Pathology Department, Mansoura University, Mansoura, Egypt Sahar ElDakroury, MD Toxicology Department, Dina ElTantawy, PhD Pathology Department, Faculty of Medicine, Sara ElDosouky, MSc Medical Experimental Research Center (MERC), 333
2 Therapeutic Advances in Neurological Disorders 3 (6) of pramipexole in a severe progressive PD model using the MPTP/paraquat combination would improve our judgment of the drug s neuroprotectant capacity. Materials and methods MPTP/paraquat mouse model and drug administration: Thirty (8-month-old) male BALB/c mice (20 25 g) were purchased from Vacsera animal house (Cairo, Egypt). All animal experiments were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, and the protocols were approved by the Ethical Committee for Research at Mansoura University. The animals were divided into three s (10 mice each):. The control received only saline via intraperitoneal route, twice per week.. The MPTP/paraquat received a combination of MPTP (Sigma-Aldrich, 30mg/kg i.p.) þ paraquat (Sigma-Aldrich, 15 mg/kg i.p.) twice per week.. The MPTP/paraquat þ pramipexole received a combination of MPTP (30mg/kg i.p.) þ paraquat (15 mg/kg i.p.) twice per week. Pramipexole was given orally at 1 mg/kg/day. In vivo assessment of the model (mortality rate) An endpoint of this experiment was the death of intoxicated animals. Each animal received both toxins twice weekly until either severe incapacitation and death or completion of eight consecutive doses. The severity of PD manifestations was measured according to the mortality rate in each. Immunohistochemistry After death (or completion of eight consecutive doses), treated mice were perfused through the aorta with 50 ml of 10 mm phosphate-buffered saline (PBS), followed by 150 ml of a cold fixative consisting of 4% paraformaldehyde, 0.35% glutaraldehyde, and 0.2% picric acid in 100 mm phosphate buffer (PB), under deep anesthesia with pentobarbital (100 mg/kg, i.p.). After perfusion, the brain was quickly removed and postfixed for 2 days with paraformaldehyde in 100 mm PB and then transferred to 15% sucrose solution in 100 mm PB containing 0.1% sodium azide at 4 C. Brains were cut into 30-mm-thick sections using a cryostat and collected in 100 mm PBS containing 0.3% Triton X-100 (PBS-T). After several washes, the sections were stored until use in a free-floating state at 4 C for immunohistochemical analysis. Brain slices were incubated with primary mouse monoclonal anti-tyrosine hydroxylase (TH) antibody (diluted 1 : 1000 Sigma) overnight at 4 C. After several washes, sections were incubated with biotinylated (goat antimouse) secondary antibody (1 : 500), for 1 h at room temperature. The sections were then incubated with ABC solution 1 : 200 for 1 h at room temperature. All of the sections were washed several times with PBS-T between each incubation, and labeling was then revealed by 3,3 0 -diaminobenzidine (DAB). Stereological analysis of dopamine neurons in the ventral midbrain TH-immunopositive neurons in the substantia nigra pars compacta (SNpc) were estimated using stereological counts of cell numbers, on a Stereo-investigator system and optical density measurements on a Leica Q-win system). Six (30-mm-thick) sections, from the anterior to the posterior midbrain, were used for counting in each case. The total number of TH-immunopositive neurons was estimated using the optical fractionator method. Statistical methods All data were given as the mean±standard error of the mean (SEM). Two s of data were analyzed by Student s t-test. Three s of data were analyzed by analysis of variance (ANOVA) with a Tukey post hoc test. For all tests, p < 0.05 was deemed significant. Results Effect of MPTP/paraquat on nigrostriatal dopamine neurons in mice As shown in Figures 1 and 2 the toxin combination severely reduced the number of TH-immunopositive neurons in the SNpc in combination with the control. Stereological analysis of nigral TH-immunopositive neurons showed that MPTP/paraquat caused severe loss of dopamine neurons (Table 1)
3 SG ElHak, AA Ghanem et al. Table 1. Stereological cell counts in the substantia nigra. (A) Control (B) MPTP/ paraquat (C) MPTP/paraquat þ pramipexole 18,700± ±30* 4770±20* *p < 0.05 compared with the control. Figure 1. Tyrosine hydroxylase immunohistochemistry in the control. Figure 3. Tyrosine hydroxylase immunohistochemistry in the MPTP/paraquat þ pramipexole. Medium magnification (20x) images in dorsolateral region of substantia nigra show no evidence of improvement. Table 2. Mortalities in the s. Figure 2. Tyrosine hydroxylase (TH) immunohistochemistry in the MPTP/paraquat. Medium magnification (20x) images in dorsolateral region of substantia nigra show severe cell loss (some areas showing complete absences of TH immunoreactive cells) in this particularly vulnerable area. (A) Control (B) MPTP/paraquat 0 10* 10* *p < 0.05 compared with the control. (C) MPTP/paraquat þ pramipexole Effect of MPTP/paraquat on mortality rate The toxin combination produced a 100% mortality rate. Effects of pramipexole on the induced neurodegeneration Upon investigation of whether treatment with pramipexole (oral 1 mg/kg/day) protects dopamine neurons from damage caused by the chronic MPTP/paraquat administration, we found no improvement regarding TH-immunopositive neurons number in the SNpc (Figure 3). Effects of pramipexole on mortality rates Pramipexole treatment did not show protection against mortality as the same mortality rate (100%) was observed in the pramipexole-treated (Table 2). Discussion Although animal models represent the first step in examining candidate anti- Parkinsonian drugs, 335
4 Therapeutic Advances in Neurological Disorders 3 (6) the results usually show different effects when applied clinically [Shimohama et al. 2003]. This limitation has led some authors to ask for a rethink of animal model strategy [Emborg, 2004]. Others have asked for more matching of the animal model to the intended objective, i.e. some will be suitable to study mechanisms while others are better suited for investigational drug testing [Lane and Dunnett, 2008]. Another suggestion has been to test candidate drugs among various models to get what is called broad spectrum neuroprotectants [Anderson et al. 2006]. The value of this multiple testing approach would apply in the case of pramipexole. Previous work has shown its potential as a neuroprotectant in PD models, e.g. MPTP and rotenone [Inden et al. 2009; Hall et al. 1996]. However, in our study pramipexole revealed no neuroprotective effect. This finding is in accordance with the work of Kemmerer and colleagues and Jeon and colleagues with 6-OH dopamine lesioned rats [Jeon et al. 2007; Kemmerer et al. 2003]. Our work represents a severe grade of PD, simulating the end stage of the disease. The use of death or severe debilitation of the tested animals can be used to assess the severity of neuronal degeneration [Cannon et al. 2009]. Furthermore, mortality rate can be used to assess the capacity of certain drug to offer neuroprotection. The variable effects of pramipexole among different models led Anderson and colleagues to assume that different toxin protocols will give different results [Anderson et al. 2006]. On our side, we think that different grades of severity would be the causative factor for variable pramipexole effects. What supports our opinion is that pramipexole failed in both 6-OH dopamine lesions and in our study using a combination of high doses of MPTP/paraquat, where in these models severe degeneration of dopaminergic neurons is expected. In contrast, pramipexole succeeded in cases of rotenone or MPTP models where there is mild neurodegeneration. These findings would suggest that severe neurodegeneration can overwhelm the protective capacity of pramipexole and diminish their effects on neurogenesis [Winner et al. 2009; He et al. 2008; Riaz and Bradford, 2005]. Conclusion Pramipexole failed to exert neuroprotection in a severe model of MPTP/paraquat-induced Parkinson s disease in mice. This failure underscores the importance of testing candidate drugs against multiple models with different degeneration severity in order to obtain a so-called wide spectrum neuroprotectant. Funding This work was supported by the Medical Experimental Research Center (MERC) of Mansoura University. Conflict of interest statement None declared. References Anderson, D.W., Bradbury, K.A. and Schneider, J.S. (2006) Neuroprotection in Parkinson models varies with toxin administration protocol. Eur J Neurosci 24: Cannon, J.R., Tapias, V., Mee, H., Honick, A., Drolet, R. and Greenamyre, J.T. (2009) A highly reproducible rotenone model of Parkinson s disease. Neurobiol Dis 34: Dawson, T.M., Mandir, A.S. and Lee, M.K. (2002) Animal models of PD: pieces of the same puzzle? Neuron 35: Emborg, M.E. (2004) Evaluation of animal models of Parkinson s disease for neuroprotective strategies. J Neurosci Meth 139: Hall, E.D., Andrus, P.K., Oostveen, J.A., Althaus, J.S. and Vonvoigtlander, P.F. (1996) Neuroprotective effects of the dopamine D2/3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res 742: He, X.J., Yamauchi, H., Uetsuka, K. and Nakayama, H. (2008) Neurotoxicity of MPTP to migrating neuroblasts: Studies in acute and subacute mouse models of Parkinson s disease. NeuroToxicology 29: Hedlund, E. and Perlmann, T. (2009) Neuronal cell replacement in Parkinson s disease. J Intern Med 266: Inden, M., Kitamura, Y., Tamaki, A., Yanagida, T., Shibaike, T., Yamamoto, A. et al. (2009) Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice. Neurochem Int 55: Jeon, M.Y., Lee, W.Y., Kang, H.Y. and Chung, E.J. (2007) The effects of L-3,4- dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the 336
5 SG ElHak, AA Ghanem et al. progressive hemiparkinsonian rat models. Neurol Res 29: Kemmerer, E.S., Desmond, T.J., Albin, R.L., Kilbourn, M.R. and Frey, K.A. (2003) Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole. Exp Neurol 183: 1 3. Lane, E. and Dunnett, S. (2008) Animal models of Parkinson s disease and L-dopa induced dyskinesia: How close are we to the clinic? Psychopharmacology 199: Riaz, S.S. and Bradford, H.F. (2005) Factors involved in the determination of the neurotransmitter phenotype of developing neurons of the CNS: Applications in cell replacement treatment for Parkinson s disease. Progress Neurobiol 76: Richter, F., Hamann, M. and Richter, A. (2008) Moderate degeneration of nigral neurons after repeated but not after single intrastriatal injections of low doses of 6-hydroxydopamine in mice. Brain Res 1188: Shepherd, K., Lee, E., Schmued, L., Jiao, Y., Ali, S., Oriaku, E. et al. (2006) The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice. Pharmacol Biochem Behav 83: Shimohama, S., Sawada, H., Kitamura, Y. and Taniguch, T. (2003) Disease model: Parkinson s disease. TRENDS Mol Med 9: Spencer, P.S., Palmer, V.S. and Ludolph, A.C. (2005) On the decline and etiology of high-incidence motor system disease in West Papua (Southwest New Guinea). Mov Disord 20(Suppl. 12): S199 S126. Winner, B., Desplats, P., Hagl, C., Klucken, J., Aigner, R., Ploetz, S. et al. (2009) Dopamine receptor activation promotes adult neurogenesis in an acute Parkinson model. Exp Neurol 219: Visit SAGE journals online
Modeling Parkinson s disease: systems to test gene-environment interactions
Modeling Parkinson s disease: systems to test gene-environment interactions Jason Cannon, Ph.D. Pittsburgh Institute of Neurodegenerative Diseases University of Pittsburgh Outline Parkinson s disease (PD)
More informationProtective effect of ginsenoside Rg1 against MPTP-induced apoptosis in mouse substantia nigra neurons 1
Chen XC et al / Acta Pharmacol Sin 2002 Sep; 23 (9): 829-834 829 2002, Acta Pharmacologica Sinica ISSN 1671-4083 Shanghai Institute of Materia Medica Chinese Academy of Sciences http://www.chinaphar.com
More informationNEUROPLASTICITY IN THE NIGROSTRIATAL SYSTEM OF MPTP-TREATED MICE AT THE PRESYMPTOMATIC AND EARLY SYMPTOMATIC STAGES OF PARKINSONISM
NEUROPLASTICITY IN E NIGROSTRIATAL SYSTEM OF MPTP-TREATED MICE AT E PRESYMPTOMATIC AND EARLY SYMPTOMATIC STAGES OF PARKINSONISM Michael V. Ugrumov Institute of Developmental Biology RAS, Moscow, Russia
More informationNeuroprotection in preclinical models of Parkinson disease by the NAPVSIPQ peptide
Neuroprotection in preclinical models of Parkinson disease by the NAPVSIPQ peptide Bruce H. Morimoto, Ph.D. Executive Director, Applied Translational Medicine Microtubules Microtubules essential for neuronal
More informationTHE EXPRESSION OF INOS IN MOUSE EXPERIMENTAL MODEL POINTS TO INFLAMMATORY CONDITIONS ASSOCIATED WITH PARKINSON S DISEASE
THE EXPRESSION OF INOS IN MOUSE EXPERIMENTAL MODEL POINTS TO INFLAMMATORY CONDITIONS ASSOCIATED WITH PARKINSON S DISEASE Fatima Laiche Noureddine Djebli Mostaganem University, Algeria Abstract Parkinson
More informationAvailable online at
Journal of Basic and Clinical PATHOPHYSIOLOGY Available online at http://jbcp.shahed.ac.ir/ Volume 4, Number 1, Autumn-Winter 2015-2016 Malva sylvestris aqueous extract could ameliorate 6-hydroxydopamine-induced
More informationAdverse outcome pathways to bridge the gap between epidemiology and experimental neurotoxicology
Adverse outcome pathways to bridge the gap between epidemiology and experimental neurotoxicology Marcel Leist In Vitro Toxicology and Biomedicine Doerenkamp-Zbinden Chair, University of Konstanz, Germany
More informationNeurodegenerative Disease. April 12, Cunningham. Department of Neurosciences
Neurodegenerative Disease April 12, 2017 Cunningham Department of Neurosciences NEURODEGENERATIVE DISEASE Any of a group of hereditary and sporadic conditions characterized by progressive dysfunction,
More informationMovement Disorders: A Brief Overview
Movement Disorders: A Brief Overview Albert Hung, MD, PhD Massachusetts General Hospital Harvard Medical School August 17, 2006 Cardinal Features of Parkinsonism Tremor Rigidity Bradykinesia Postural imbalance
More informationThe role of FGF-9 expression in neuroprotection of melatonin and MPP + -induced parkinsonism model in vivo and in vitro Key words: FGF-9; melatonin;
-9 參 神 MPP + 神 : -9; ; MPP + ; 神 ; 狀 (FGFs)(FGFRs) 理 復 23 FGFs, FGF-2 FGF-9 神 :, 了 FGFs 年來 金, 神 神 (MPP + ) 神 IGFBDNFFGF-9 FGF 神 不 神 FGF-9 量 FGF-9 神 FGF-9 參 神 MPP + 狀 狀 FGF-9 mrna 量 狀 tyrosine hydroxylase
More informationNovel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson s disease
Baranyi et al. Molecular Neurodegeneration (2016) 11:6 DOI 10.1186/s13024-015-0067-y RESEARCH ARTICLE Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson
More informationSupplementary Materials for. c-abl Activation Plays a Role in α-synucleinopathy Induced Neurodegeneration
Supplementary Materials for c-abl Activation Plays a Role in α-synucleinopathy Induced Neurodegeneration Saurav Brahmachari, Preston Ge, Su Hyun Lee, Donghoon Kim, Senthilkumar S. Karuppagounder, Manoj
More informationThe Pennsylvania State University The Graduate School College of Health and Human Development HOST SUSCEPTIBILITY TO ENVIRONMENTAL TOXICANTS
The Pennsylvania State University The Graduate School College of Health and Human Development HOST SUSCEPTIBILITY TO ENVIRONMENTAL TOXICANTS A Dissertation in Biobehavioral Health by Gelareh Alam 2015
More informationNIH Public Access Author Manuscript Parkinsonism Relat Disord. Author manuscript; available in PMC 2009 January 1.
NIH Public Access Author Manuscript Published in final edited form as: Parkinsonism Relat Disord. 2008 ; 14(Suppl 2): S84 S87. doi:10.1016/j.parkreldis.2008.04.004. Strengths and Limitations of Genetic
More informationSanneke van Vliet, Raymond Vanwersch, Marjan Jongsma, Jan van der Gugten, Berend Olivier, Ingrid Philippens
Neuroprotective effects of Δ 9 -tetrahydrocannabinol in a marmoset Parkinson model Sanneke van Vliet, Raymond Vanwersch, Marjan Jongsma, Jan van der Gugten, Berend Olivier, Ingrid Philippens Manuscript
More informationIvyspring International Publisher. Int. J. Med. Sci. 2014, Vol. 11. Abstract
1049 Research Paper Ivyspring International Publisher International Journal of Medical Sciences 2014; 11(10): 1049-1064. doi: 10.7150/ijms.8182 Opposite Effects of Bone Marrow-Derived Cells Transplantation
More informationPERSPECTIVE. Localized striatal delivery of GDNF as a treatment for Parkinson disease. Deniz Kirik, Biljana Georgievska & Anders Björklund
Localized striatal delivery of GDNF as a treatment for Parkinson disease Deniz Kirik, Biljana Georgievska & Anders Björklund Ten years ago, a glial cell line derived neurotrophic factor (GDNF) that has
More informationGreen Tea Polyphenol Epigallocatechin-3-Gallate Attenuates Behavioral Abnormality in Hemi-Parkinsonian Rat
Iranian Biomedical Journal 1 (4): 23-27 (October 26) Green Tea Polyphenol Epigallocatechin-3-Gallate Attenuates Behavioral Abnormality in Hemi-Parkinsonian Rat Tourandokht Baluchnejadmojarad *1 and Mehrdad
More informationThis is a free sample of content from Parkinson's Disease. Click here for more information or to buy the book.
A AADC. See Aromatic amino acid decarboxylase AAV. See Adeno-associated virus Acetylcholine (ACh), functional imaging, 174 175 ACh. See Acetylcholine Adaptive immune system central nervous system, 381
More informationAlterations of nocturnal activity in rats following subchronic oral administration of the neurotoxin 1-trichloromethyl-1,2,3,4-tetrahydro-b-carboline
J Neural Transm (2009) 116:1267 1271 DOI 10.1007/s00702-009-0261-6 MOVEMENT DISORDERS - ORIGINAL ARTICLE Alterations of nocturnal activity in rats following subchronic oral administration of the neurotoxin
More informationThe Pitx3-deficient aphakia mouse: a naturally occurring mouse model of dopamine deficiency van den Munckhof, P.
UvA-DARE (Digital Academic Repository) The Pitx3-deficient aphakia mouse: a naturally occurring mouse model of dopamine deficiency van den Munckhof, P. Link to publication Citation for published version
More informationMaking Every Little Bit Count: Parkinson s Disease. SHP Neurobiology of Development and Disease
Making Every Little Bit Count: Parkinson s Disease SHP Neurobiology of Development and Disease Parkinson s Disease Initially described symptomatically by Dr. James Parkinson in 1817 in An Essay on the
More informationGene Therapy (2003) 10, & 2003 Nature Publishing Group All rights reserved /03 $
(2003) 10, 1721 1727 & 2003 Nature Publishing Group All rights reserved 0969-7128/03 $25.00 www.nature.com/gt REVIEW Gene therapy progress and prospects: Parkinson s disease EA Burton 1, JC Glorioso 2
More informationThe Opportunity: Parkinson s disease, RLS, ADHD, and disease modification YKP10461
The Opportunity: Parkinson s disease, RLS, ADHD, and disease modification YKP10461 1 TABLE OF CONTENTS Profile Summary Mechanism of Action Clinical Study Results Pharmacologic Profile Safety and Toxicity
More informationAnalysis of inflammation-related nigral degeneration and locomotor function in DJ-1 / mice
Nguyen et al. Journal of Neuroinflammation 213, 1:5 JOURNAL OF NEUROINFLAMMATION RESEARCH Open Access Analysis of inflammation-related nigral degeneration and locomotor function in DJ-1 / mice Thi A Nguyen
More informationCURRICULUM VITAE. Jonathan Dickerson B.S. Biology, Wilmington College.
CURRICULUM VITAE Jonathan Dickerson Education: 1999-2003 B.S. Biology, Wilmington College. 2004-2010 Ph.D., Neuroscience Graduate Program, University of Cincinnati. Thesis Advisor: Dr. Kim Seroogy 2007
More informationSmoking, nicotine and Parkinson s disease
Review TRENDS in Neurosciences Vol.27 No.9 September 2004 Smoking, nicotine and Parkinson s disease Maryka Quik The Parkinson s Institute, 1170 Morse Avenue, Sunnyvale, CA 94089, USA Epidemiological studies
More informationParkinson s disease (PD) is a neurodegenerative disorder that mainly affects individuals
Behavioral treatment of rotational behavior in the rat model of Parkinson s disease Parkinson s disease (PD) is a neurodegenerative disorder that mainly affects individuals 50 years and older. Degeneration
More informationBORDEAUX MDS WINTER SCHOOL FOR YOUNG
BORDEAUX MDS WINTER SCHOOL FOR YOUNG NEUROLOGISTS HOW TO EVALUATE MOTOR COMPLICATIONS IN PARKINSON'S DISEASE T. Henriksen Tove Henriksen, MD MDS Clinic University Hospital of Bispebjerg, Copenhagen MOTOR
More informationDown regulation of the HCN2 channel in rat models of Parkinson s disease
Down regulation of the HCN2 channel in rat models of Parkinson s disease Abstract The basal ganglia is a key control centre involved with the regulation of movement. It is therefore a primary interest
More informationTestosterone Replacement Attenuates Haloperidol-Induced Catalepsy in Male Rats
Advanced Pharmaceutical Bulletin, 2014, 4(3), 237-241 doi: http://dx.doi.org/10.5681/apb.2014.034 http://apb.tbzmed.ac.ir/ Testosterone Replacement Attenuates Haloperidol-Induced Catalepsy in Male Rats
More informationA Parkinson s Disease and related disorders
A 3.5.2 Parkinson s Disease and related disorders 10 November 2016 Marinela Vavla marinela.vavla@kcl.ac.uk Learning objectives Basal ganglia: components and localization (inter)connections and functions
More informationIntroduction. Cheongju, Chungbuk 28644, Korea
Natural Product Sciences 22(3) : 187-192 (2016) http://dx.doi.org/10.20307/nps.2016.22.3.187 Effects of Gypenosides on Dopaminergic Neuronal Cell Death in 6-Hydroxydopamine-lesioned Rat Model of Parkinson
More information1. INTRODUCTION Parkinson's disease (PD)
1. INTRODUCTION Parkinson's disease (PD) is a pathological condition that has been known for centuries through early Greek scientific descriptions, traditional Indian texts and ancient Chinese sources.
More informationImpact of the Secretome of Human Mesenchymal Stem Cells on Brain Structure and Animal Behavior in a Rat Model of Parkinson s Disease
Impact of the Secretome of Human Mesenchymal Stem Cells on Brain Structure and Animal Behavior in a Rat Model of Parkinson s Disease FABIO G. TEIXEIRA,MIGUEL M.CARVALHO KRISHNA M. PANCHALINGAM ANA J.RODRIGUES
More informationMotor Fluctuations in Parkinson s Disease
Motor Fluctuations in Parkinson s Disease Saeed Bohlega, MD, FRCPC Senior Distinguished Consultant Department of Neurosciences King Faisal Specialist Hospital & Research Centre Outline Type of fluctuations
More informationThis article was published in an Elsevier journal. The attached copy is furnished to the author for non-commercial research and education use, including for instruction at the author s institution, sharing
More informationHYPERBARIC OXYGEN TREATMENT ON A PARKINSON S DISEASE PATIENT: A CASE STUDY Hoggard ML, Johnson KE and Shirachi DY. Chico Hyperbaric Center, Chico, CA
HYPERBARIC OXYGEN TREATMENT ON A PARKINSON S DISEASE PATIENT: A CASE STUDY Hoggard ML, Johnson KE and Shirachi DY. Chico Hyperbaric Center, Chico, CA 95926 and Department of Physiology and Pharmacology,
More informationEmbargoed until Oct. 18, 10:30 a.m. CDT Contacts: Kat Snodgrass, (202) Press Room, Oct : (312) Sarah Bates, (202)
Embargoed until Oct. 18, 10:30 a.m. CDT Contacts: Kat Snodgrass, (202) 962-4090 Press Room, Oct. 17 21: (312) 791-6619 Sarah Bates, (202) 962-4087 RUN FOR YOUR LIFE: NEW STUDIES SHOW BENEFITS OF EXERCISE
More informationGBME graduate course. Chapter 43. The Basal Ganglia
GBME graduate course Chapter 43. The Basal Ganglia Basal ganglia in history Parkinson s disease Huntington s disease Parkinson s disease 1817 Parkinson's disease (PD) is a degenerative disorder of the
More informationTITLE: Neurotrophic Response to CNS Degeneration or Injury: Effects of Aging
AD Award Number: DAMD17-01-1-0766 TITLE: Neurotrophic Response to CNS Degeneration or Injury: Effects of Aging PRINCIPAL INVESTIGATOR: David M. Yurek, Ph.D. Kim B. Seroogy, Ph.D. CONTRACTING ORGANIZATION:
More informationTyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by l-dopa
European Journal of Neuroscience, Vol. 27, pp. 580 592, 2008 doi:10.1111/j.1460-9568.2008.06040.x Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be
More informationAnalysis of volatile organic compounds in rats with dopaminergic lesion: possible application for early detection of Parkinson s disease
Oxidative Stress laboratory Analysis of volatile organic compounds in rats with dopaminergic lesion: possible application for early detection of Parkinson s disease By Dr. Soliman Khatib Senior lecturer,
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Treatment Advances Tuesday, January 26, 2016 Welcome and Introductions Stephanie Paul Vice President Development and Marketing American Parkinson Disease Association 1
More informationKinematic Modeling in Parkinson s Disease
Kinematic Modeling in Parkinson s Disease Alexander Hui Department of Bioengineering University of California, San Diego La Jolla, CA 92093 alexhui@ucsd.edu Abstract Parkinson s disease is a slowly progressing
More informationStem Cells and The Endometrium. Director, Division of Reproductive Endocrinology and infertility
Stem Cells and The Endometrium Hugh S. Taylor, M.D. Director, Division of Reproductive Endocrinology and infertility Nothing to disclose Stem Cells Cells that are capable of both self-renewal and have
More informationTITLE: Pharmacological and Behavioral Enhancement of Neuroplasticity in the MPTP- Lesioned Mouse and Nonhuman Primate
AD Award Number: W81XWH-04-1-0444 TITLE: Pharmacological and Behavioral Enhancement of Neuroplasticity in the MPTP- Lesioned Mouse and Nonhuman Primate PRINCIPAL INVESTIGATOR: Giselle Petzinger, M.D. Michael
More information-Synuclein Overexpression Protects against Paraquat- Induced Neurodegeneration
The Journal of Neuroscience, April 15, 2003 23(8):3095 3099 3095 Brief Communication -Synuclein Overexpression Protects against Paraquat- Induced Neurodegeneration Amy B. Manning-Boğ, Alison L. McCormack,
More informationSupplementary Figure 1
Supplementary Figure 1 Localization of virus injections. (a) Schematic showing the approximate center of AAV-DIO-ChR2-YFP injection sites in the NAc of Dyn-cre mice (n=8 mice, 16 injections; caudate/putamen,
More informationResearch Article Effect of Quercetin in the 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-Induced Mouse Model of Parkinson s Disease
Evidence-Based Complementary and Alternative Medicine Volume 12, Article ID 928643, 6 pages doi:1.1155/12/928643 Research Article Effect of Quercetin in the 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-Induced
More informationAtsushi Fujita 1, Hiroo Yamaguchi 1, Ryo Yamasaki 1, Yiwen Cui 1, Yuta Matsuoka 2, Ken-ichi Yamada 2 and Jun-ichi Kira 1*
Fujita et al. Journal of Neuroinflammation (2018) 15:227 https://doi.org/10.1186/s12974-018-1251-0 RESEARCH Open Access Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration
More informationReview Article Classic and New Animal Models of Parkinson s Disease
Journal of Biomedicine and Biotechnology Volume 2012, Article ID 845618, 10 pages doi:10.1155/2012/845618 Review Article Classic and New Animal Models of Parkinson s Disease Javier Blesa, 1, 2 Sudarshan
More informationClinical Study Intensive Rehabilitation Treatment in Parkinsonian Patients with Dyskinesias: A Preliminary Study with 6-Month Followup
Parkinson s Disease Volume 2012, Article ID 910454, 4 pages doi:10.1155/2012/910454 Clinical Study Intensive Rehabilitation Treatment in Parkinsonian Patients with Dyskinesias: A Preliminary Study with
More informationThis student paper was written as an assignment in the graduate course
77:222 Spring 2003 Free Radicals in Biology and Medicine Page 0 This student paper was written as an assignment in the graduate course Free Radicals in Biology and Medicine (77:222, Spring 2003) offered
More informationDRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer
DRUG TREATMENT OF PARKINSON S DISEASE Mr. D.Raju, M.pharm, Lecturer PARKINSON S DISEASE (parkinsonism) is a neurodegenerative disorder which affects t h e b a s a l g a n g l i a - and is associated with
More informationAlkaloids from piper longum protect dopaminergic neurons against inflammation-mediated damage induced by intranigral injection of lipopolysaccharide
He et al. BMC Complementary and Alternative Medicine (2016) 16:412 DOI 10.1186/s12906-016-1392-6 RESEARCH ARTICLE Open Access Alkaloids from piper longum protect dopaminergic neurons against inflammation-mediated
More informationGypenosides ameliorate memory deficits in MPTP-lesioned mouse model of Parkinson s disease treated with L-DOPA
Zhao et al. BMC Complementary and Alternative Medicine (2017) 17:449 DOI 10.1186/s12906-017-1959-x RESEARCH ARTICLE Open Access Gypenosides ameliorate memory deficits in MPTP-lesioned mouse model of Parkinson
More informationThe Pitx3-deficient aphakia mouse: a naturally occurring mouse model of dopamine deficiency van den Munckhof, P.
UvA-DARE (Digital Academic Repository) The Pitx3-deficient aphakia mouse: a naturally occurring mouse model of dopamine deficiency van den Munckhof, P. Link to publication Citation for published version
More informationRecombinant adenovirus carrying glial cell line2derived neurotrophic factor gene protect midbra in dopaminergic neurons in mice
256 ( ) JOURNAL OF PEKIN G UNIVERSITY( HEAL TH SCIENCES) Vol. 35 No. 3 J une 2003 ( 100083) [ ] ; ;MPTP [ ] : (r GDNF) (DA) 2 2 (MPTP) :LacZ (Ad2LacZ) 24 h 72 h 10 d 30 d X2Gal ;r GDNF (Ad2r GDNF) 72 h
More informationn-propanol extract of boiled and fermented koro benguk (Mucuna pruriens seed) shows a neuroprotective effect in paraquat
Veterinary World, EISSN: 2231-0916 RESEARCH ARTICLE Open Access n-propanol extract of boiled and fermented koro benguk (Mucuna pruriens seed) shows a neuroprotective effect in paraquat dichloride-induced
More informationFrancardo, Veronica; Recchia, Alessandra; Popovic, Nataljia; Andersson, Daniel; Nissbrandt, Hans; Cenci Nilsson, Angela
Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease. Francardo, Veronica; Recchia, Alessandra;
More informationAlzheimer's Disease A mind in darkness awaiting the drink of a gentle color.
Alzheimer's Disease A mind in darkness awaiting the drink of a gentle color. Mary ET Boyle, Ph. D. Department of Cognitive Science UCSD Gabriel García Márquez One Hundred Years of Solitude Alois Alzheimer
More informationParkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817.
Parkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817. Four (4) hallmark clinical signs: 1) Tremor: (Note -
More informationRole of the IL-1 Pathway in Dopaminergic Neurodegeneration and Decreased Voluntary Movement
Mol Neurobiol (217) 54:4486 4495 DOI 1.17/s1235-16-9988-x Role of the IL-1 Pathway in Dopaminergic Neurodegeneration and Decreased Voluntary Movement Andrea Stojakovic 1 & Gilberto Paz-Filho 2 & Mauricio
More informationAn Exploratory Evaluation of Tyrosine Hydroxylase Inhibition in Planaria as a Model for Parkinsonism
Int. J. Mol. Sci. 2013, 14, 23289-23296; doi:10.3390/ijms141223289 Technical Note OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms An Exploratory Evaluation
More informationDamage on one side.. (Notes) Just remember: Unilateral damage to basal ganglia causes contralateral symptoms.
Lecture 20 - Basal Ganglia Basal Ganglia (Nolte 5 th Ed pp 464) Damage to the basal ganglia produces involuntary movements. Although the basal ganglia do not influence LMN directly (to cause this involuntary
More informationChapter 8. Parkinsonism. M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University.
Chapter 8 Parkinsonism M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University. Definition of Parkinson s Disease Parkinson's disease is a progressive, neurodegenerative disease
More informationImpairment of Neurogensis in the Olfactory Bulb of Transgenic Mice Overexpressing Human Wildtype Alpha Synuclein Under the Thy-1 Promoter
Impairment of Neurogensis in the Olfactory Bulb of Transgenic Mice Overexpressing Human Wildtype Alpha Synuclein Under the Thy-1 Promoter Parkinson s disease (PD) is a progressive neurodegenerative disorder
More informationGetting involved in Parkinson s disease
Getting involved in Parkinson s disease DEVELOPING AND EXPLOITING C. ELEGANS MODEL FOR PARKINSON S DISEASE Supported by the PD society Anton Gartner, Ph.D. University of Dundee MSI/WTB Complex Gene Regulation
More informationTitle: Restorative Effects of Uridine Plus Docosahexaenoic Acid in a Rat Model of Parkinson's Disease
Elsevier Editorial System(tm) for Neuroscience Research Manuscript Draft Manuscript Number: NSR-D-08-00172R1 Title: Restorative Effects of Uridine Plus Docosahexaenoic Acid in a Rat Model of Parkinson's
More informationThe locus coeruleus Is Directly Implicated in L-DOPA-Induced Dyskinesia in Parkinsonian Rats: An Electrophysiological and Behavioural Study
The locus coeruleus Is Directly Implicated in L-DOPA-Induced Dyskinesia in Parkinsonian Rats: An Electrophysiological and Behavioural Study Miguelez, Cristina; Aristieta, Asier; Cenci Nilsson, Angela;
More informationTREATMENT-SPECIFIC ABNORMAL SYNAPTIC PLASTICITY IN EARLY PARKINSON S DISEASE
TREATMENT-SPECIFIC ABNORMAL SYNAPTIC PLASTICITY IN EARLY PARKINSON S DISEASE Angel Lago-Rodriguez 1, Binith Cheeran 2 and Miguel Fernández-Del-Olmo 3 1. Prism Lab, Behavioural Brain Sciences, School of
More informationTITLE: Pharmacological and Behavioral Enhancement of Neuroplasticity in the MPTP- Lesioned Mouse and Nonhuman Primate
AD Award Number: W81XWH-04-1-0444 TITLE: Pharmacological and Behavioral Enhancement of Neuroplasticity in the MPTP- Lesioned Mouse and Nonhuman Primate PRINCIPAL INVESTIGATOR: Giselle Petzinger, M.D. Michael
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Addressing Motor and Non-Motor Symptoms The Changing Landscape Wednesday, March 8, 2017 Welcome and Introductions Stephanie Paul Vice President Development and Marketing
More informationMoving Ahead With Mixtures: Environmental Chemical Exposures as Risk Factors for Human Diseases and Disorders
Moving Ahead With Mixtures: Environmental Chemical Exposures as Risk Factors for Human Diseases and Disorders Deborah A. Cory Slechta Department of Environmental Medicine University of Rochester School
More informationPh D THESIS ABSTRACT
ALEXANDRU IOAN CUZA UNIVERSITY IAŞI FACULTY OF BIOLOGY THE STUDY OF CHANGES FOR SEVERAL BIOCHEMICAL PARAMETERS OF OXIDATIVE STRESS IN ANIMAL MODELS FOR NEUROPSYCHIATRIC DISORDERS Ph D THESIS ABSTRACT Scientific
More informationScott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE
Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical
More informationKEY SUMMARY. Mirapexin /Sifrol (pramipexole): What it is and how it works. What is Mirapexin /Sifrol (pramipexole)?
KEY SUMMARY 1. Mirapexin /Sifrol (pramipexole*) is a selective non-ergot dopamine agonist approved as immediate release since 1997 for the treatment of the signs and symptoms of idiopathic Parkinson's
More informationEffects of 6-hydroxydopamine on the Adult Neurogenesis of Dopaminergic Neurons in the Mouse Midbrain
Experimental Neurobiology Vol. 18, pages 26 31, June 2009 Effects of 6-hydroxydopamine on the Adult Neurogenesis of Dopaminergic Neurons in the Mouse Midbrain Tae Woo Kim, Hyun Kim and Woong Sun* Department
More informationSullivan, Aideen M.; Toulouse, André. Article (peer-reviewed)
Title Author(s) Neurotrophic factors for the treatment of Parkinson's disease Sullivan, Aideen M.; Toulouse, André Publication date 2011-06 Original citation Type of publication Link to publisher's version
More informationVisualization and simulated animations of pathology and symptoms of Parkinson s disease
Visualization and simulated animations of pathology and symptoms of Parkinson s disease Prof. Yifan HAN Email: bctycan@ust.hk 1. Introduction 2. Biochemistry of Parkinson s disease 3. Course Design 4.
More informationParkinson's Disease KP Update
Parkinson's Disease KP Update Andrew Imbus, PA-C Neurology, Movement Disorders Kaiser Permanente, Los Angeles Medical Center No disclosures "I often say now I don't have any choice whether or not I have
More informationPHARMACOLOGICAL RESCUE OF PARKINSON S DISEASE SYMPTOMS. A Thesis. Presented to. The College of Arts and Sciences. Ohio University
1 PHARMACOLOGICAL RESCUE OF PARKINSON S DISEASE SYMPTOMS WITH DROSOPHILA LARVAE A Thesis Presented to The College of Arts and Sciences Ohio University In Partial Fulfillment of the Requirements for Graduation
More informationTITLE: Caffeine, Adenosine Receptors and Estrogen in Toxin Models of Parkinson s Disease
AWARD NUMBER: W81XWH-04-1-0881 TITLE: Caffeine, Adenosine Receptors and Estrogen in Toxin Models of Parkinson s Disease PRINCIPAL INVESTIGATOR: Michael A. Schwarzschild, M.D., Ph.D. CONTRACTING ORGANIZATION:
More informationTITLE: Pharmacological and Behavioral Enhancement of Neuroplasticity in the MPTP- Lesioned Mouse and Nonhuman Primate.
AD Award Number: W81XWH-04-1-0444 TITLE: Pharmacological and Behavioral Enhancement of Neuroplasticity in the MPTP- Lesioned Mouse and Nonhuman Primate. PRINCIPAL INVESTIGATOR: Giselle M. Petzinger, M.D.
More informationExecutive Summary
------------------------------------------------------ Executive Summary Vietnam Service, Chemical Exposure and Parkinson s disease (PD) ------------------------------------------------------ Executive
More informationCitation for published version (APA): Peng, S. (2015). ips cell therapy for Parkinson s disease [Groningen]: University of Groningen
University of Groningen ips cell therapy for Parkinson s disease Peng, Suping IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationToshiyuki Kawasaki, Kotaro Ishihara, Yukio Ago, Akemichi Baba, and Toshio Matsuda
0022-3565/07/3221-274 281$20.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 322, No. 1 Copyright 2007 by The American Society for Pharmacology and Experimental Therapeutics 119206/3219369
More informationSymptom-relieving and neuroprotective effects of the phytocannabinoid D 9 -THCV in animal models of Parkinson s disease
1495..156 BJP British Journal of Pharmacology DOI:1.1111/j.1476-5381.211.1278.x www.brjpharmacol.org Themed Issue: Cannabinoids in Biology and Medicine, Part I RESEARCH PAPERbph_1278 Symptom-relieving
More informationEffect of epigallocatechin-3-gallate on inflammatory mediators release in LPSinduced Parkinson's disease in rats
Indian Journal of Exprimental Biology Vol. 52, May 2013, pp. 357-362 Effect of epigallocatechin-3-gallate on inflammatory mediators release in LPSinduced Parkinson's disease in rats Jehan S AL-amri 1,
More informationExperimental change on dopaminergic neurons in striatum of Parkinson disease rats
Histol Histopathol (2007) 22: 1085-1090 DOI: 10.14670/HH-22.1085 http://www.hh.um.es Histology and Histopathology Cellular and Molecular Biology Experimental change on dopaminergic neurons in striatum
More informationTime course behavioral features are correlated with Parkinson's disease associated pathology in a 6 hydroxydopamine hemiparkinsonian rat model
3356 MOLECULAR MEDICINE REPORTS 17: 3356-3363, 2018 Time course behavioral features are correlated with Parkinson's disease associated pathology in a 6 hydroxydopamine hemiparkinsonian rat model RUI JUN
More informationUSING PRECISION MEDICINE TO HELP PATIENTS WITH PARKINSON S DISEASE. The Michael J. Fox Foundation for Parkinson s Research
USING PRECISION MEDICINE TO HELP PATIENTS WITH PARKINSON S DISEASE The Michael J. Fox Foundation for Parkinson s Research MJFF IS THE WORLD S LARGEST NONPROFIT FUNDER OF PD RESEARCH Our Mission We are
More informationBasal Ganglia. Steven McLoon Department of Neuroscience University of Minnesota
Basal Ganglia Steven McLoon Department of Neuroscience University of Minnesota 1 Course News Graduate School Discussion Wednesday, Nov 1, 11:00am MoosT 2-690 with Paul Mermelstein (invite your friends)
More informationDEVELOPING A NOVEL ANIMAL MODEL FOR THE STUDY OF PARKINSON S DISEASE: FOCUSING ON THE EARLY LOSS OF NORADRENERGIC NEURONS
DEVELOPING A NOVEL ANIMAL MODEL FOR THE STUDY OF PARKINSON S DISEASE: FOCUSING ON THE EARLY LOSS OF NORADRENERGIC NEURONS by Stephanie Marie Foster A thesis submitted in partial fulfillment of the requirements
More informationPresented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn
Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Objectives What agents do we currently have available and what do we ideally need? What biomarkers exist for
More informationTO BE MOTIVATED IS TO HAVE AN INCREASE IN DOPAMINE. The statement to be motivated is to have an increase in dopamine implies that an increase in
1 NAME COURSE TITLE 2 TO BE MOTIVATED IS TO HAVE AN INCREASE IN DOPAMINE The statement to be motivated is to have an increase in dopamine implies that an increase in dopamine neurotransmitter, up-regulation
More informationNON-MOTOR SYMPTOMS IN PARKINSON S DISEASE: MODELING AND MECHANISMS
From the DEPARTMENT OF NEUROSCIENCE Karolinska Institutet, Stockholm, Sweden NON-MOTOR SYMPTOMS IN PARKINSON S DISEASE: MODELING AND MECHANISMS Débora Masini Stockholm 2018 All previously published papers
More informationThe motor regulator. 1) Basal ganglia/nucleus
The motor regulator 1) Basal ganglia/nucleus Neural structures involved in the control of movement Basal Ganglia - Components of the basal ganglia - Function of the basal ganglia - Connection and circuits
More informationCopyright 2012 Cognizant Comm. Corp. E-ISSN
Cell Transplantation, Vol. 21, pp. 1629 1640, 2012 0963-6897/12 $90.00 +.00 Printed in the USA. All rights reserved. DOI: http://dx.doi.org/10.3727/096368912x640556 Copyright 2012 Cognizant Comm. Corp.
More information